2023-05-03 16:35:34 ET
- Allogene Therapeutics press release ( NASDAQ: ALLO ): Q1 GAAP EPS of -$0.68 misses by $0.06 .
- Revenue of $0.05M (-16.7% Y/Y) beats by $0.04M .
- Research and development expenses were $80.2 million for the first quarter of 2023, which includes $9.2 million of non-cash stock-based compensation expense.
- General and administrative expenses were $18.9 million for the first quarter of 2023, which includes $9.6 million of non-cash stock-based compensation expense.
- The Company had $514 million in cash, cash equivalents, and investments as of March 31, 2023.
- 2023 Financial Guidance
- The Company now expects a decrease in cash, cash equivalents, and investments of approximately $230 million in 2023.
For further details see:
Allogene Therapeutics GAAP EPS of -$0.68 misses by $0.06, revenue of $0.05M beats by $0.04M